AbbVie Inc (ABBV)vsSight Sciences Inc (SGHT)
ABBV
AbbVie Inc
$294.64
-0.16%
HEALTHCARE · Cap: $520.47B
SGHT
Sight Sciences Inc
$10.59
-2.22%
HEALTHCARE · Cap: $601.92M
Smart Verdict
WallStSmart Research — data-driven comparison
AbbVie Inc generates 74581% more annual revenue ($66.01B vs $88.39M). ABBV leads profitability with a 15.7% profit margin vs -32.1%. ABBV earns a higher WallStSmart Score of 77/100 (B+).
ABBV
Strong Buy77
out of 100
Grade: B+
SGHT
Avoid27
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-87.6%
Fair Value
$157.25
Current Price
$294.64
$137.39 premium
Margin of Safety
+33.3%
Fair Value
$8.29
Current Price
$10.59
$2.30 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 62 in profit
Strong operational efficiency at 36.6%
Earnings expanding 2282.0% YoY
Conservative balance sheet, low leverage
Growing faster than its price suggests
Revenue surging 25.2% year-over-year
Areas to Watch
Premium valuation, high expectations priced in
Distress zone — elevated risk
Trading at 11.9x book value
0.0% earnings growth
Smaller company, higher risk/reward
ROE of -57.8% — below average capital efficiency
Comparative Analysis Report
WallStSmart ResearchBull Case : ABBV
The strongest argument for ABBV centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 15.7% and operating margin at 36.6%. Revenue growth of 10.3% demonstrates continued momentum.
Bull Case : SGHT
The strongest argument for SGHT centers on Revenue Growth. Revenue growth of 25.2% demonstrates continued momentum.
Bear Case : ABBV
The primary concerns for ABBV are P/E Ratio, Altman Z-Score. A P/E of 50.6x leaves little room for execution misses.
Bear Case : SGHT
The primary concerns for SGHT are Price/Book, EPS Growth, Market Cap.
Key Dynamics to Monitor
ABBV profiles as a mature stock while SGHT is a growth play — different risk/reward profiles.
SGHT carries more volatility with a beta of 2.40 — expect wider price swings.
SGHT is growing revenue faster at 25.2% — sustainability is the question.
ABBV generates stronger free cash flow (7.3B), providing more financial flexibility.
Bottom Line
ABBV scores higher overall (77/100 vs 27/100), backed by strong 15.7% margins and 10.3% revenue growth. SGHT offers better value entry with a 33.3% margin of safety. Both earn "Strong Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AbbVie Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AbbVie is an American publicly traded biopharmaceutical company founded in 2013. It originated as a spin-off of Abbott Laboratories.
Sight Sciences Inc
HEALTHCARE · MEDICAL DEVICES · USA
Sight Sciences Inc. (SGHT) is an innovative medical technology company specializing in the advancement of treatments for ocular diseases, with a particular emphasis on glaucoma management through both surgical and non-surgical approaches. The company’s diverse product portfolio, supported by a robust intellectual property framework, positions it favorably as demand for minimally invasive ophthalmic therapies escalates. By focusing on enhancing patient outcomes and refining its distribution network, Sight Sciences is set to capture significant market share in the evolving healthcare landscape, making it a noteworthy opportunity for institutional investors seeking growth in the medical technology sector.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?